ChemImage Announces Release of Lower Cost Falcon II™ Wide-Field Raman Chemical Imaging Platforms

New Editions of the FALCON II Wide-Field Raman Chemical Imaging System to Provide an Economic Option for Pharmaceutical Organizations Seeking to Obtain More Accurate Drug Particle Size Distribution Measurements

PITTSBURGH, PA – ChemImage Corporation, a world leader in chemical imaging technologies, is pleased to announce the release of lower cost configurations of their FALCON II Wide-field Raman Chemical Imaging systems. This technology provides the opportunity for pharmaceutical companies and contract research organizations (CROs) to more effectively develop orally inhaled and nasal drug products (OINDP) by providing fast, accurate ingredient-specific particle size distribution measurements – now available for a more affordable price.

The reengineered and refined FALCON II Professional, Plus, Standard and Lite Series’ enables drug developers to obtain Raman chemical images (RCI) for Ingredient-Specific Particle Sizing (ISPS™) and other applications, while offering the same great technology and results as seen from previous platforms.

“We recognize the economical need of drug developers in today’s economy. We have continued to work toward advances in Raman chemical imaging through our FALCON II product platform to offer the same great technology at a more economical price,” says Jim McGlone, President of ChemImage Corporation.

ChemImage’s Hyperspectral Imaging technology allows users to study particles in droplets of a nasal spray suspension or individual particles in pulmonary drug delivery systems and enables users to distinguish the chemical identity, particle size and distribution of drug and other substances, as well as aggregation, and other characteristics of the material in the formulation.

According to Thomas Voigt, Executive VP, the technology allows generic drug manufacturers to lower the risk when going into clinical trials by providing them with additional bioequivalency data. All pulmonary and nasal drug developers and formulators can utilize ChemImage’s products and laboratory services to perform in vitro drug particle size distribution measurements, identify chemical makeup of aggregates, as well as study and understand the stability of the formulation.

Innovators can also utilize the technology to develop hard to duplicate formulations. The value of the chemical image comes from the importance of knowing where drug particles are in relation to other materials and how they are distributed. This imaging technology provides an opportunity for drug development and product advances, including use as part of batch release testing.

ChemImage Corporation, headquartered in Pittsburgh, is a world leader in Chemical Imaging technologies; provides instrumentation, software, laboratory services, and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Its state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.